Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 12:12 pm Purchase | 2025-06-30 | 13G | KARYOPHARM THERAPEUTICS INC CO KPTI | T. Rowe Price Investment Management, Inc. | 728,766 8.400% | 728,766 (New Position) | Filing History |
| 2025-07-16 09:34 am Purchase | 2025-06-30 | 13G | KARYOPHARM THERAPEUTICS INC CO KPTI | JPMorgan Chase & Co. JPM | 450,436 5.200% | 450,436 (New Position) | Filing History |
| 2025-04-10 5:23 pm Purchase | 2025-04-03 | 13G | KARYOPHARM THERAPEUTICS INC CO KPTI | Affinity Asset Advisors, LLC | 664,224 7.830% | 664,224 (New Position) | Filing History |
| 2025-02-12 09:36 am Purchase | 2024-12-31 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | Adage Capital Management, L.P. | 436,737 5.180% | 436,737 (New Position) | Filing History |
| 2024-11-14 4:22 pm Sale | 2024-09-30 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | Avidity Partners Management LP | 316,071 3.700% | -429,845 (-57.63%) | Filing History |
| 2024-11-12 3:50 pm Unchanged | 2024-09-30 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | VANGUARD GROUP INC | 510,299 6.130% | 0 (Unchanged) | Filing History |
| 2024-11-04 11:49 am Sale | 2024-09-30 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | VANGUARD GROUP INC | 510,299 6.130% | -70,378 (-12.12%) | Filing History |
| 2024-10-25 09:30 am Purchase | 2024-09-30 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | Highbridge Capital Management, LLC | 649,659 7.200% | 649,659 (New Position) | Filing History |
| 2024-07-08 4:32 pm Sale | 2024-06-30 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | BlackRock, Inc. BLK | 277,986 3.500% | -393,459 (-58.60%) | Filing History |
| 2024-05-23 4:30 pm Purchase | 2024-05-13 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | J. Wood Capital Advisors LLC | 458,135 5.500% | 458,135 (New Position) | Filing History |
| 2024-02-14 4:52 pm Sale | 2023-12-31 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | Palo Alto Investors LP | 340,146 4.450% | -36,899 (-9.79%) | Filing History |
| 2024-02-14 10:33 am Sale | 2023-12-31 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | Avidity Partners Management LP | 745,916 9.500% | -12,822 (-1.69%) | Filing History |
| 2024-02-13 5:07 pm Purchase | 2023-12-29 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | VANGUARD GROUP INC | 580,677 7.600% | 580,677 (New Position) | Filing History |
| 2024-02-12 06:06 am Sale | 2023-12-31 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | Rubric Capital Management LP | 0 0.000% | -552,975 (Position Closed) | Filing History |
| 2024-01-25 1:48 pm Purchase | 2023-12-31 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | BlackRock, Inc. BLK | 671,445 8.800% | 104,229 (+18.38%) | Filing History |
| 2024-01-22 1:50 pm Sale | 2023-12-31 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | STATE STREET CORP STT | 136,918 1.790% | -10,573 (-7.17%) | Filing History |
| 2023-07-10 2:26 pm Sale | 2023-06-30 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | STATE STREET CORP STT | 147,491 1.940% | -404,978 (-73.30%) | Filing History |
| 2023-02-14 4:21 pm Purchase | 2022-12-31 | 13G | EPIZYME INC EPZM | Palo Alto Investors LP | 5,655,676 5.000% | 5,655,676 (New Position) | Filing History |
| 2023-02-14 4:06 pm Sale | 2022-12-31 | 13G | KARYOPHARM THERAPEUTICS INC KPTI | Commodore Capital LP | 129,041 1.700% | -138,362 (-51.74%) | Filing History |
| 2023-02-14 3:41 pm Sale | 2022-12-31 | 13G | KARYOPHARM THERAPEUTICS INC CO KPTI | Chione Ltd. | 293,333 3.900% | -40,000 (-12.00%) | Filing History |